Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chapman, T.
Right arrow Articles by Morris, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chapman, T.
Right arrow Articles by Morris, J. C.
Neurology 2000;55:1396-1398
© 2000 American Academy of Neurology
Brief Communications

Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt–Jakob disease

T. Chapman, MD, D. W. McKeel, Jr., MD and J. C. Morris, MD

From the Departments of Neurology (Dr. Morris) and Pathology (Drs. McKeel and Morris), Washington University School of Medicine, St. Louis, MO.

Address correspondence and reprint requests to Dr. John C. Morris, Department of Neurology, Box 8111-ADRC, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110; e-mail: morrisj@ neuro.wustl.edu

The definitive diagnosis of Creutzfeldt–Jakob disease (CJD) requires brain tissue analysis. A positive assay for the 14-3-3 protein in CSF has been suggested to be highly sensitive and specific in patients with CJD. The authors describe three patients for whom CSF 14-3-3 assays were falsely positive or falsely negative. Caution against overreliance on this putative biomarker is suggested in the diagnosis of CJD.




This article has been cited by other articles:


Home page
 Arch NeurolHome page
M. D. Geschwind, K. M. Tan, V. A. Lennon, R. F. Barajas Jr, A. Haman, C. J. Klein, S. A. Josephson, and S. J. Pittock
Voltage-Gated Potassium Channel Autoimmunity Mimicking Creutzfeldt-Jakob Disease
Arch Neurol, October 1, 2008; 65(10): 1341 - 1346.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
B R J Van Everbroeck, J Boons, and P Cras
14-3-3 {gamma}-isoform detection distinguishes sporadic Creutzfeldt-Jakob disease from other dementias
J. Neurol. Neurosurg. Psychiatry, January 1, 2005; 76(1): 100 - 102.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
A. J. Aksamit
Cerebrospinal Fluid 14-3-3 Protein: Variability of Sporadic Creutzfeldt-Jakob Disease, Laboratory Standards, and Quantitation
Arch Neurol, June 1, 2003; 60(6): 803 - 804.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
M. D. Geschwind, J. Martindale, D. Miller, S. J. DeArmond, J. Uyehara-Lock, D. Gaskin, J. H. Kramer, N. M. Barbaro, and B. L. Miller
Challenging the Clinical Utility of the 14-3-3 Protein for the Diagnosis of Sporadic Creutzfeldt-Jakob Disease
Arch Neurol, June 1, 2003; 60(6): 813 - 816.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
K. Peoc'h, P. Beaudry, N. Laupretre, J.-L. Laplanche, P. R. Burkhard, J.-C. Sanchez, T. Landis, and D. F. Hochstrasser
CSF detection of the 14-3-3 protein in unselected patients with dementia
Neurology, February 12, 2002; 58(3): 509 - 510.
[Full Text] [PDF]

Home page
 NeurologyHome page
A. J. E. Green, R. S. G. Knight, M. A. Macleod, A. Lowman, R. G. Will, T. Chapman, D. W. McKeel Jr., and J. C. Morris
Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease
Neurology, April 10, 2001; 56(7): 986 - 987.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by AAN Enterprises, Inc.